Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 single-arm study of hydroxocobalamin chloride injection in pediatric cblC-type methylmalonic acidemia with elevated homocysteine
CTR20253147Phase 3Active
- Sponsor
- CSPC ZhongQi Pharmaceutical Technology
- Start
- Oct 2025
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Metabolically Activated Prodrugs → Prodrugs/Conditional Activator Small Molecules → Small Molecules
- Countries
- 1
01
Overview
A Phase 3 trial of hydroxocobalamin in methylmalonic acidemia (MMA), sponsored by CSPC ZhongQi Pharmaceutical Technology. Started Oct 2025; status: active.
02
Drugs
hydroxocobalamin
03
Conditions
methylmalonic acidemia (MMA)
Beyond the preview
Go deeper on CTR20253147.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20253147.